retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Eli Lilly just announced striking results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% From Obesity to Metabolic Health:
Description
This is likely caused by the glucagon receptor component
Many people with these conditions use GLP-1 medications successfully, but medical appropriateness depends on your complete health profile
Thus, incretin therapy influences not just metabolism but also sensory and reward pathways. Taste changes tied to satiety, appetite In multivariable analysis, adults who reported increased intensity for sweet taste had higher odds of increased satiety (adjusted OR = 2.02
01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
CKS is only available in the UK
Ultracentrifugal studies of lipoproteins of human serum
